Quinazolines exhibit various biological activities. In the present investigation a series of new 2-amino-5-aryl-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ols are synthesized by the condensation of various naphthyl substituted cyclohexenones with guanidine in presence of NaOEt. All the synthesized compounds are characterized by various spectral techniques.
Introduction
Quinazoline and its derivatives are a class of heteroaromatic compounds that have drawn much attention because of their pharmacological properties. Members of this family have wide applications in medicinal chemistry, being used as antimalarial, anti-inflammatory, antiasthmatic, antibacterial, antihypertensive, tyrosine kinase inhibiting agents, antituberculars, antiparkinsons, antihelmintics, CNS depressant and they also show blood platelet anti-aggregating activity (Billker et al. 1998; Chen et al. 2001) . Derivatives of aminoquinazolines are potent inhibitors of Growth Factor Receptor (GFR) tyrosine kinases and have found clinical applications in Epidermal and vascular Endotherlial targets (Bridges et al. 1996; Wakeling et al. 2005 ).
In particular, Gefinitib (traded as Iressa, ZD1839) has been recognized as a tyrosine kinase inhibitor of the epidermal growth factor receptor and has been clinically used against cell lung cancer with ever increasing popularity. The quinazoline-dependent kinase (QDK) family of enzymes plays a vital role in the control of cell-cycle progression, particularly at cell-cycle check points. Aberrant cell cycle control, arising from tumour suppressor gene malfunction or oncogene activation, is associated with increase QDK/quinazoline activity in human tumours (Sherr, 1996; Malumbres & Barbacid, 2001 ).
As a consequence aminoquinazolines are very attractive target molecules in synthetic organic chemistry. Keeping in view the biological importance of the above mentioned heterocyclic compounds, and pursuing our research on pyrimidine derivatives (Chandrasekaran & Nagarajan, 2005; Ingarsal et al. 2007) , we report herein the synthesis of 2-amino-5,6-dihydro-5-aryl-7-(naphthalen-2-yl)quinazolin-4-ol's from ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-enecarboxylate. The synthesized compounds are characterized by various spectral techniques.
Results and discussion
The 2-aminoquinazolinols are synthesized in three steps (Scheme 1) starting from easily available 2-acetylnaphthalene and substituted benzaldehyde. The 2-naphthyl-3-arylpropen-2-en-1-ones, 3a-l was obtained by treatment of 2-naphthylethanone with different aromatic aldehydes in presence of base. Naphthylethanone was prepared by acetylation of naphthalene in presence of anhydrous aluminium chloride. The reaction of compounds 3a-l with ethyl acetoacetate in presence of sodium ethoxide gave ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-ene carboxylate. The target compounds 2-amino-5-aryl-5,6-dihydro-7-naphthylquinazolin-4-ols 5a-l were obtained by treatment of 4a-l with guanidine hydrochloride in presence of sodium ethoxide (Scheme 1). The products 5a-l were purified by column chromatography (CHCl 3 ; MeOH; 4:1). Yield, melting point, reaction time and elemental analyses are mentioned in Table 1 and 2.
The IR spectra of the compounds 5a-l displays characteristic absorption bands in the region of 3380, 2922, 1600, 1350, 1230 . The 1 H NMR shows characteristic peaks for 5a at 3.14 (d, 1H, J = 13. 33.8, 41.3, 113.7, 123.3, 136 .2 and other signals for aromatic and ipso carbons.
Experimental
All chemicals were of analytical grade and solvents were distilled before use. Melting points were uncorrected and determined in open capillaries. The 1 H NMR and 13 C NMR were recorded on Brucker Amx-500 spectrometer operating at 500 MHz using DMSO-d 6 as solvent. The FT-IR spectra were recorded on NICOLET AVATAR 360 FT-IR instrument by using KBr pellets. Elemental analysis were done on EL.CHNO elemental analyzer.
Preparation of 1-(l-naphthyl)ethanone (2) A mixture of 41.9g (38 mL, 0.53 mol) of acetyl chloride and 100 mL of carbon tetrachloride was taken in a one-litre three necked flask. The flask was equipped with condenser carrying a guard tube and a dropping funnel. About 70g (0.52 mol) of powdered dry AlCl 3 was added slowly to the vigorously stirred mixture. The mixture was cooled to 20°C and a solution of naphthalene (32g, 0.25 mol) in 100 mL of CCl 4 was added for 90 minutes from the dropping funnel. The hydrogen chloride was evolved. After the completion of the addition, the mixture was warmed to 30°C for 30 minutes. The resulting mixture was decomposed with ice and concentrated hydrochloric acid. The product was separated and the crude was distilled under reduced pressure b.p 165°C/15 mm Hg.
Preparation of naphthyl chalcones (3a-l) 2-Acetylnaphthalene (0.01 mole) was dissolved in ethanol and added to a solution containing NaOH (0.5g) aromatic aldehyde (0.01 mole). The mixture was refluxed for about 2 hours. The resulting mixture was poured into cold water. The product was further purified by recrystallisation from EtOH.
General procedure for the synthesis of ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-ene carboxylate (4a-l)
A mixture of chalcone 3a-l (0.01 mole) and sodium ethoxide (2 g sodium in 60 ml ethanol) with freshly distilled ethyl acetoacetate (0.01 mole) was dissolved in absolute ethanol (30 ml) and refluxed for eight hours. The reaction mixture was kept aside for more than one hour and the yellow solid mass obtained was collected and recrystallized from ethanol. All the compounds were characterized with IR and NMR spectroscopy.
2-Amino-5-aryl-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ols (5a-l) Appropriate cyclohexenones (4a-l, 0.01 mole) and guanidine hydrochloride (0.01 mole) in the presence of sodium ethoxide (2 g in 30 ml ethanol) were refluxed for 16-23 hours. The reaction mixture was cooled to room temperature and poured into crushed ice and stirred well. The separated product was purified using column chromatography silica gel, CHCl 3 -MeOH, 4:1. All the compounds were characterized using IR, = 33.8, 41.3, 113.9, 123.3 , 123.5, 123.9, 124.5, 125.8, 126.0, 126.4, 126.9, 127.3, 128.3, 130.9, 132.2, 132.9, 136.2, 136.7, 143.0, 144.6, 154.2, 162.3. 2-Amino-5-(4-chlorophenyl)-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ol (5b): White solid; IR (KBr) ( max , cm = 33.8, 41.3, 113.2, 123.3, 123.6, 123.9, 124.5, 125.8, 126.0, 126.2, 126.9, 127.3, 128.0, 128.3, 130.9, 132.2, 132.7, 132.9, 136.2, 136.7, 143.0, 144.6, 154.2, 162. 113.6, 120.2, 123.3, 124.0, 124.5, 125.8, 126.2, 126.5, 126.7, 126.9, 127.7, 128.3, 128.5, 130.7, 132.7, 132.8, 134 .9 and C-6 merged with DMSO signal.
2-Amino-5-(3-chlorophenyl)-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ol (5d) = 35.3, 43.7, 113.5, 123.5, 123.9, 124.4, 126.5, 126.6, 126.9, 127.3, 127.4, 128.0, 129.0, 132.8, 133.5, 135.1, 135.7, 140.8, 154.7, 163 = 32.3, 113.2, 123.2, 123.6, 124.4, 126.5, 126.8, 127.4, 127.5, 127.8, 128.1, 128.2, 128.3, 129.2, 129.5, 132.2, 132.4, 132.7, 1330, 136.3, 140.2, 142.5, 155.1, 162.2. 2-Amino-5,6-dihydro-7-naphthyl-5-(3-nitrophenyl)quinazolin-4-ol (5f): Brownish Solid; IR (KBr) ( max , cm  1 ): 3398, 1651, 3057, 1216, 1375, 1498 ; 1 H NMR = (ppm) 3.12 (d, 1H, H-6, J = 13.6 Hz), 3.22-3.29 (m, 1H, H-6) = 33.4, 113.6, 123.3, 123.8, 124.6, 125.9, 126.4, 124.5, 127.8, 128.1, 129.4, 129.8, 130.2, 130.9, 132.9, 136.0, 143.0, 144.0, 155.2, = 33.2, 113.8, 123.3, 123.8, 124.6, 125.9, 126.2, 126.4, 126.5, 127.3, 127.8, 128.1, 128.4, 129.2, 130.2, 130.9, 136.0, 143.0, 144.0, 155., 162 .4, C-6 merged with DMSO.
2-Amino-5-(4-methoxyphenyl)-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ol (5h): Brownish Solid; IR (KBr) ( max , cm  1 ): 3339, 1650, 3056, 1247, 1298; 1 H NMR = (ppm) 2.26 (CH 3 ) 3.10 (d, 1H, H-6, J= 13.6), 3.24-3.19 (m, 1H, H-6), 4.21 (d,1H, H-5, J = 6.6 Hz), 6.38 (s, NH 2 ), 6.73 (s, 8H), 6.96-8.05 (Ar-H), 10.69 (-OH);
13 C NMR = 20.7 (-OCH 3 ), 33.6, 106.8, 123.3, 123.4, 123.9, 124.4, 126.4, 126.5, 126.8, 127.3, 127.8, 128.0, 128.3, 128.5, 132.7, 132.9, 134.8, 141.5, 142.9, 154.9, 162 .5, C-6 merged with DMSO.
2-Amino-5-(4-bromophenyl)-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ol (5i) = 113.1, 123.0, 124.9, 125.2, 125.5, 126.1, 126.5, 127.9, 128.6, 129.8, 130.2, 132.7, 133.2, 136.0, 141.3, 143.8, 144.1, 144.6, 152.9, 160 .3. C-5 and C-6merged with DMSO signal.
2-Amino-5-(4-fluorophenyl)-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ol (5j) = 33.6, 113.8, 123.4, 124.5, 126.2, 126.6, 127.3, 127.7, 128.0, 128.2, 128.3, 128.8, 130.7, 132.7, 132.9, 136.3, 136.6, 136.9, 142.9, 152.0, 162.4 and C-6merged with DMSO signal. = 33.5, 113.4, 123.3, 123.4, 123.6, 124.6, 124.9, 125.9, 126.2, 126.4, 126.5, 126.9, 127.3, 127.7, 127.9, 128.1, 128.2, 128.4, 128.7, 130.3, 130.6, 131.1, 132.2, 132.8, 133.6, 133.6, 143.0, 143.5, 154.2, 158 .0 and C-6 merged DMSO signal. = 113.5, 123.7, 128.2, 129.3, 129.5, 129.9, 130.9, 141.3, 146.9, 149.9, 153.6, 155.6, 158 .1 and C-5 and C-6 merged with DMSO signal.
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